SOPHiA GENETICS Enhances Cancer Detection Collaboration with AstraZeneca

SOPHiA GENETICS Expands Collaboration with AstraZeneca

SOPHiA GENETICS, a pioneering AI technology firm specializing in precision medicine, has affirmed its commitment to enhancing cancer care by broadening its collaboration with AstraZeneca. Announced during the World CB CDx Summit held in Boston on September 22, 2025, this partnership focuses on refining the diagnosis and treatment methods for breast and prostate cancers through an advanced next-generation sequencing (NGS) solution.

The cutting-edge sequencing technology will capitalize on SOPHiA's proprietary AI algorithms to identify critical genetic mutations in the PIK3CA/AKT1/PTEN pathway—an essential molecular signaling network that governs cell growth and survival. Disruptions in this pathway are significantly linked to cancer progression, including breast and prostate cancers. Of particular concern is the alteration of the PTEN gene, which has been associated with cancer development and reduced effectiveness of cancer treatments.

As part of the newly expanded collaboration, SOPHiA GENETICS and AstraZeneca have come together to develop an optimized NGS solution. This solution will allow for comprehensive analysis and greater sensitivity in detecting mutations across the entire range of the PTEN gene, addressing the complexities associated with cancer genetic profiling.

Initial prototypes of this enhanced analysis tool have already shown promising results, exhibiting improved sensitivity in detecting intricate mutations in the PIK3CA/AKT1/PTEN pathway. To validate these developments, SOPHiA GENETICS plans to implement a Privileged Access Program at selected clinical laboratories dedicated to breast and prostate cancer research. This phase is critical for assessing the tool’s sensitivity in actual clinical environments, with results expected to further affirm its effectiveness.

SOPHiA GENETICS anticipates making the new NGS solution commercially available by 2026. Alongside this rollout, a multi-center real-world evidence study will be initiated to continue evaluating the tool's performance and effectiveness in diagnosing cancer in diverse patient populations. The initiative aims not just to advance diagnostic capabilities but also to increase accessibility to personalized cancer treatment options, ultimately improving outcomes for patients worldwide.

“The ongoing collaboration with esteemed biopharma leaders like AstraZeneca is essential in leveraging recent advancements in our understanding of cancer,” said Ross Muken, President of SOPHiA GENETICS. “Together, we aim to transform these insights into actionable solutions for breast and prostate cancer patients globally, marking a significant stride in our mission to democratize data-driven healthcare.”

The alliance underscores the mutual commitment shared by SOPHiA GENETICS and AstraZeneca to innovate in the field of precision oncology. Through their combined expertise, they seek to ensure that advanced genomic testing and targeted therapies are accessible to a broader patient base around the world.

For those interested in exploring further, SOPHiA GENETICS will be showcasing their developments at the World CB CDx Summit in Boston from September 22-25, 2025. To learn more about their initiatives, visit SOPHiAGENETICS.COM or engage with them on LinkedIn.

About SOPHiA GENETICS

SOPHiA GENETICS, trading under Nasdaq: SOPH, is dedicated to expanding the accessibility of data-driven medicine. By employing AI technologies, the company efficiently provides top-tier cancer care and addresses rare disorders. Their flagship SOPHiA DDM™ Platform is designed to analyze complex genomic data, providing actionable insights that benefit a global network of hospitals, laboratories, and biopharmaceutical organizations. For additional insights into their offerings, visit SOPHiAGENETICS.COM and connect on LinkedIn.

Please note that SOPHiA GENETICS's products are intended for Research Use Only and are not authorized for diagnostic procedures unless specified. The information herein may vary by country and may or may not have regulatory approvals. For specific product details based on your location, reach out to the company directly.